2021-09-22 22:30
After safety review The Connection study is now again open to recruit the smallest infants.
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee)...
2021-09-10 12:30
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican...
2021-08-25 12:50
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the...
2021-08-13 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2021
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development...
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August...
2021-05-20 16:30
Infant Bacterial Therapeutics CFO leaves the company
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during...
2021-05-06 18:50
Annual General Meeting of Infant Bacterial Therapeutics CEO speech
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics...
2021-05-04 17:00
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: About Infant Bacterial...
2021-05-04 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program...
2021-04-29 22:00
Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams
After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500...